The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

被引：0
|
作者：
Toshihiko Doi
Yutaka Fujiwara
Kohei Shitara
Toshio Shimizu
Kan Yonemori
Nobuaki Matsubara
Izumi Ohno
Takahiro Kogawa
Yoichi Naito
Lance Leopold
Mihaela Munteanu
Naoyoshi Yatsuzuka
Shi Rong Han
Ayman Samkari
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital East,Department of Experimental Therapeutics
[2] National Cancer Center Hospital,Department of Experimental Therapeutics
[3] Mitsui Memorial Hospital,Department of Respiratory Medicine
[4] Incyte Corporation,Department of Clinical Oncology
[5] Clinical Development,undefined
[6] MSD K.K. Oncology Science Unit,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
Investigational New Drugs | 2021年 / 39卷
关键词：
Advanced solid tumors; Epacadostat (INCB024360); Japanese; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：152 / 162
页数：10
相关论文
共 50 条
  • [1] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
    Doi, Toshihiko
    Fujiwara, Yutaka
    Shitara, Kohei
    Shimizu, Toshio
    Yonemori, Kan
    Matsubara, Nobuaki
    Ohno, Izumi
    Kogawa, Takahiro
    Naito, Yoichi
    Leopold, Lance
    Munteanu, Mihaela
    Yatsuzuka, Naoyoshi
    Han, Shi Rong
    Samkari, Ayman
    Yamamoto, Noboru
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 152 - 162
  • [2] KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer
    Yamamoto, Noboru
    Satouchi, Miyako
    Doi, Toshihiko
    Fujiwara, Yutaka
    Yanagitani, Noriko
    Kawa, Yoshitaka
    Yoh, Kiyotaka
    Leopold, Lance
    Munteanu, Mihaela
    Sawada, Takashi
    Han, Shirong
    Noguchi, Kazuo
    Nishio, Makoto
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 261 - 271
  • [3] Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
    Powderly, John D.
    Klempner, Samuel J.
    Naing, Aung
    Bendell, Johanna
    Garrido-Laguna, Ignacio
    Catenacci, Daniel V. T.
    Taylor, Matthew H.
    Lee, James J.
    Zheng, Fred
    Zhou, Feng
    Gong, Xiaohua
    Gowda, Hema
    Beatty, Gregory L.
    ONCOLOGIST, 2022, 27 (11) : 905 - E848
  • [4] A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
    Kasuga, Akiyoshi
    Nakagawa, Kazuhiko
    Nagashima, Fumio
    Shimizu, Toshio
    Naruge, Daisuke
    Nishina, Shinichi
    Kitamura, Hiroshi
    Kurata, Takayasu
    Takasu, Atsuko
    Fujisaka, Yasuhito
    Okamoto, Wataru
    Nishimura, Yuichiro
    Mukaiyama, Akihira
    Matsushita, Hideki
    Furuse, Junji
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1058 - 1067
  • [5] A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
    Akiyoshi Kasuga
    Kazuhiko Nakagawa
    Fumio Nagashima
    Toshio Shimizu
    Daisuke Naruge
    Shinichi Nishina
    Hiroshi Kitamura
    Takayasu Kurata
    Atsuko Takasu
    Yasuhito Fujisaka
    Wataru Okamoto
    Yuichiro Nishimura
    Akihira Mukaiyama
    Hideki Matsushita
    Junji Furuse
    Investigational New Drugs, 2015, 33 : 1058 - 1067
  • [6] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Yung-Jue Bang
    Yoon-Koo Kang
    Daniel V. Catenacci
    Kei Muro
    Charles S. Fuchs
    Ravit Geva
    Hiroki Hara
    Talia Golan
    Marcelo Garrido
    Shadia I. Jalal
    Christophe Borg
    Toshihiko Doi
    Harry H. Yoon
    Mary J. Savage
    Jiangdian Wang
    Rita P. Dalal
    Sukrut Shah
    Zev A. Wainberg
    Hyun Cheol Chung
    Gastric Cancer, 2019, 22 : 828 - 837
  • [7] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    GASTRIC CANCER, 2019, 22 (04) : 828 - 837
  • [8] Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma
    Fujiwara, Yutaka
    Takahashi, Yasuo
    Okada, Morihito
    Kishimoto, Takumi
    Kondo, Shunsuke
    Fujikawa, Koshi
    Hayama, Manabu
    Sugeno, Masatoshi
    Ueda, Shinya
    Komuro, Keiko
    Lanasa, Mark
    Nakano, Takashi
    ONCOLOGIST, 2022, 27 (09) : E703 - E722
  • [9] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Toshihiko Doi
    Narikazu Boku
    Yusuke Onozawa
    Keishiro Takahashi
    Osamu Kawaguchi
    Atsushi Ohtsu
    Investigational New Drugs, 2020, 38 : 1390 - 1399
  • [10] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Doi, Toshihiko
    Boku, Narikazu
    Onozawa, Yusuke
    Takahashi, Keishiro
    Kawaguchi, Osamu
    Ohtsu, Atsushi
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1390 - 1399
12345